Methods for expansion of mesenchymal stromal cells

A GMP-compliant method for expanding umbilical cord-derived MSCs through pre-activation and bioreactor culture addresses the limitations of BM-MSCs, producing highly immunosuppressive cells for treating inflammatory and regenerative conditions.

JP2024161089AInactive Publication Date: 2024-11-15BOARD OF RGT THE UNIV OF TEXAS SYST
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2024143439
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-10-05
Filing Date
2024-08-23
Publication Date
2024-11-15
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current methods for expanding mesenchymal stromal cells (MSCs) from bone marrow are limited by declining cell number and differentiation potential with age, inconsistent quality, and the invasive nature of bone marrow aspiration, while umbilical cord tissue-derived MSCs (CBt-MSCs) offer faster growth and similar immunosuppressive properties but lack a GMP-compliant production process.

Method used

A method for expanding CBt-MSCs involves obtaining MSCs from umbilical cord tissue, treating it with an enzyme cocktail, pre-activating with TNFα, IFNγ, IL-1β, and IL-17, and culturing in a bioreactor to achieve a high confluency, resulting in a GMP-compliant process that produces large quantities of highly immunosuppressive MSCs.

Benefits of technology

The method yields MSCs with enhanced immunosuppressive properties and higher stemness markers, capable of treating inflammatory disorders and regenerative medicine conditions, including GVHD, autoimmune diseases, and ischemic stroke, with improved efficiency and cost-effectiveness compared to BM-MSCs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024161089000001
    Figure 2024161089000001
  • Figure 2024161089000002
    Figure 2024161089000002
  • Figure 2024161089000003
    Figure 2024161089000003
Patent Text Reader

Abstract

To provide the expansion of populations of mesenchymal stromal cells (MSCs) and its use.SOLUTION: Provided herein are methods for expanding populations of mesenchymal stromal cells (MSCs) comprising a step for treating a population of MSCs derived from cord tissue with a pre-activation cytokine cocktail. Further provided herein are methods of treating immune disorders with the MSCs.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] (CROSS-REFERENCE TO RELATED APPLICATIONS) This application is the benefit of U.S. Provisional Patent Application No. 62 / 741,933, filed October 5, 2018. This provisional application is incorporated herein by reference in its entirety.

[0002] background 1. Field The present invention relates generally to the fields of medicine and immunology. More particularly, the present invention relates to mesenchymal stem cells. The present invention relates to the expansion of human stromal cells and uses thereof. [Background technology]

[0003] 2. Description of Related Technology Over the past decade, bone marrow-derived mesenchymal stromal cells (BM-MSCs) have been used to treat graft-versus-host disease. in various clinical situations, including cardiovascular disease, ischemic / non-ischemic cardiovascular disease, and ischemic stroke BM-MSCs have been used therapeutically as a therapeutic agent and as a gene delivery vehicle. The number and differentiation potential of cells declines with increasing donor age, and BM-MSCs These include variable product quality and the invasive nature of the required BM aspiration procedure. After the birth of a normal infant, umbilical cord blood tissue (CBt) is typically discarded, so this starting material Collection of cells is non-invasive. CBt-MSCs can be grown faster and in greater numbers than BM-MSCs. It is possible to expand the range of CBs available for clinical use and they have similar immunosuppressive properties. There is an unmet need to develop GMP-compliant procedures for generating t-MSCs. Summary of the Invention

[0004] Abstract In a first embodiment, the present disclosure provides a method for expanding MSCs derived from the CBt. The method includes the steps of obtaining a population of MSCs from umbilical cord tissue; Presence of at least three cytokines selected from the group consisting of IL-1β and IL-17 and obtaining an expanded population of MSCs. In certain embodiments, the method further comprises expanding the pre-activated MSCs to produce a therapeutically effective amount of the MSCs. This method is GMP compliant. In some embodiments, the population of MSCs derived from umbilical cord tissue is may be pre-cryopreserved or derived from fresh or pre-cryopreserved umbilical cord tissue. Coming.

[0005] In some embodiments, the obtaining step comprises treating the umbilical cord tissue with an enzyme cocktail. The enzyme cocktail may include hyaluronidase and collagenase. In one embodiment, the collagenase is collagenase NB4 / 6. The enzyme cocktail further contains DNAse. Hyaluronidase is 0.5 to 1.5 U. / mL concentration, e.g., 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1 In some embodiments, the collagenase is a concentration of 0.1 to 1 U / mL, e.g., 0.1, 0.2, 0.3, 0.4, 0.5, 0 In certain embodiments, the DN Ase is administered at concentrations of 200-300 U / mL, e.g., 200, 225, 250, 275, or or 300 U / mL.

[0006] The MSCs are cultured at a confluency of at least 85%, e.g., 86%, 87%, or 89%, prior to preactivation. 7%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 9 The cells may be cultured to a confluency of 7%, 98%, 99%, or 100%. In this case, the MSCs are cultured for 6 to 8 days, e.g., 6, 7, or 8 days, before preactivation. In certain embodiments, at least 500 million, e.g., 600, 700, 800, 900, or more. One billion MSCs are obtained before preactivation. Preactivation lasts for 12 to 24 hours. , e.g., 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 Or it can be 24 hours.

[0007] In certain embodiments, the MSCs are capable of expressing TNFα, IFNγ, IL-1β, and IL-1β. In some embodiments, the inhibitors of TNFα, IFN-17 are preactivated. γ and / or IL-1β at a concentration of 5 to 15 ng / mL, e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 ng / mL or higher. In such cases, IL-17 is administered at a concentration of 20 to 40 ng / mL, for example, 20, 25, 30, Present at concentrations of 35, 40 ng / mL or greater.

[0008] In some embodiments, the expansion is carried out in a functionally closed system, such as a bioreactor. For example, the bioreactor is a hollow fiber bioreactor. In embodiments, the expansion is carried out for less than 7 days, e.g., 6, 5, or 4 days. , at least 50-fold, e.g., at least 55, 60, 65, 70, 75, 80-fold, or In some embodiments, the MSCs are expanded for less than 28 hours, e.g., For example, they have a doubling time of 27, 26, 25, or 24 hours. The method further comprises the step of cryopreserving the expanded MSCs.

[0009] In certain embodiments, the expanded population of MSCs exhibits greater immunosuppression than bone marrow MSCs. In some embodiments, the expanded population of MSCs has a cytogenetic phenotype. These results suggest that CBt-derived MSCs exhibit a more immunosuppressive phenotype than CBt-derived MSCs expanded without pre-activation with ATP. In certain embodiments, the immunosuppressive phenotype is characterized by the expression of anti-apoptotic factors (e.g., , VEGF and / or TGFβ), anti-inflammatory factors (e.g., TSG-6), immunomodulatory factors Expression of receptors and / or chemoattractant homing factors (e.g., CXCR4 and CXCR3) In some embodiments, the immunomodulatory factor is PD-L1, IDO , PGE2, IL-10, and TGFβ. Therefore, the expanded MSC population exhibited increased stemness markers and / or have high expression of chemokine receptors. Exemplary stemness markers include Nes tin, Stro-1, Oct-4, Nanog, and Cox-2, and chemokines The receptors include VEGF, HLA-G, PGE, CXCR4, IL-10, and In some embodiments, the expanded population of MSCs includes several immune regulatory pathways, e.g., T cell exhaustion, granulocyte adhesion and extravasation, antigen presentation pathways, Negative regulation of immune response, positive regulation of Notch signaling, and lymphocyte apoptosis process Positive regulation of ATP, adhesion and extravasation of agranulocytes, regulation of cellular responses to hypoxia, TGFβ signaling, NFKβ signaling, IL-6 signaling, iNos and Positive regulation of eNos signaling 1, STAT4 and PI3K signaling, and The expression of genes associated with the induction of T cell apoptosis was induced. The expanded MSC population expresses homing receptors and heavy metal ions involved in adhesion and invasion. High expression of genes involved in extravasation and homing, including essential adhesion molecules, was observed. Exemplary adhesion and invasion markers include GLG1, VCAM1, C XCR4, ICAM1, CSF3, CXCL3, CXCL8, SELPG, STAT1, IFITT3, ISG15, STAT2, MX1, OAS1, IFI6, JAK2, TA P1, IFI35, IFITM1, PSM89, IRF1, IFITM3, PTPN2, RELA, IFNAR2, HSP90AA1, JUN, ARNT, HIF1 and CUL 2 is an example.

[0010] The present disclosure further provides a method for treating umbilical cord tissue comprising administering a soluble collagenase, hyaluronidase, and DNase to a subject. In some embodiments, the composition comprises a composition for dissociating MSCs. The umbilical cord tissue is dissociated for isolation. In certain embodiments, the composition comprises collagen. In certain embodiments, the composition comprises DNase, hyaluronidase, and DNase. , without BSA or trypsin inhibitors, or without BSA or trypsin inhibitors For example, the collagenase is collagenase NB4 / 6. Luronidase is 0.5 to 1.5 U / mL, e.g., 0.6, 0.7, 0.8, 0.9, The concentration may be 1.0, 1.1, 1.2, 1.3, 1.4 or 1.5 U / mL. In some embodiments, collagenase is present at a concentration of 0.1 to 1 U / mL, e.g., 0.1, 0 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 or 1 U / mL In certain embodiments, the DNAse is present at a concentration of 200 to 300 U / mL, e.g., In some embodiments, the ATP concentration is 200, 225, 250, 275, or 300 U / mL. CBt-derived MSCs have been previously cryopreserved.

[0011] Further embodiments include expanded MSCs produced by the methods of the above embodiments and A pharmaceutical composition comprising a pharmaceutically acceptable carrier is provided. Compositions comprising expanded MSCs produced by the methods of the above embodiments for use in Further provided herein are, in some embodiments, the inflammatory disease is a transplant-associated disease. Graft-versus-host disease (GVHD), autoimmune diseases, acute ischemic stroke, myocardial injury, acute respiratory distress In certain embodiments, the MSCs are: They are allogeneic. They can be administered systemically or locally.

[0012] In another embodiment, a method of treating an inflammatory disease in a subject is provided, the method comprising: The method includes administering a therapeutically effective amount of CBt-derived MSCs, e.g., CBt- In certain embodiments, the subject is a human. In some embodiments, the CBt-derived MSCs have been previously cryopreserved.

[0013] In some embodiments, the inflammatory disease is GVHD, an autoimmune disease, or an acute ischemic stroke. In certain embodiments, the MSCs are allogeneic, myocardial injury, ARDS, or inflammatory bowel disease. MSCs can be administered systemically or locally. For example, MSCs can be administered intravenously, intranasally, intramuscularly, or intravenously. , buccal, vaginal, subcutaneous, intradermal, intravenous, intraperitoneal, intramuscular, intra-articular, intrasynovial, intrasternal, intrathecal The drug is administered via intralesional or intracranial routes or via an implanted reservoir. In further embodiments, the MSCs are administered with at least one additional therapeutic agent. In some embodiments, the at least one additional therapeutic agent is a therapeutically effective amount of an immunomodulatory agent or an immunosuppressant. In certain embodiments, the immunosuppressant is a calcineurin inhibitor. , mTOR inhibitors, antibodies, chemotherapeutic agents, radiation, chemokines, interleukins, or chemotherapeutic agents It is an inhibitor of kines or interleukins.

[0014] Further embodiments provide a therapeutically effective amount of CBt-derived MSCs ( For example, the use of CBt-MSCs produced according to this embodiment is provided. In some embodiments, the CBt-derived MSCs have been previously cryopreserved. Inflammatory diseases include GVHD, autoimmune diseases, acute ischemic stroke, myocardial injury, ARDS, and In certain embodiments, the MSCs are allogeneic. For example, MSCs can be administered rectally, nasally, buccally, vaginally, subcutaneously, intradermally, or topically. Intravenous, intraperitoneal, intramuscular, intra-articular, intrasynovial, intrasternal, intrathecal, intralesional or intracranial In a further embodiment, the MS C is administered with at least one additional therapeutic agent. The at least one additional therapeutic agent is a therapeutically effective amount of an immunomodulatory or immunosuppressive agent. In certain embodiments, the immunosuppressant is a calcineurin inhibitor, an mTOR inhibitor, an antibody, chemotherapy, radiation, chemokines, interleukins, or chemokines or interleukins It is an inhibitor of ikine.

[0015] Other objects, features and advantages of the present invention will become apparent from the following detailed description. However, from this detailed description, those skilled in the art will appreciate that various modifications and variations within the spirit and scope of the invention are possible. Because various modifications and variations will become apparent, the detailed description and specific examples are intended to be illustrative of the preferred embodiments of the invention. While the embodiments shown are illustrative, it should be understood that they are given by way of example only.

[0016] The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present disclosure. The present disclosure, along with the detailed description of specific embodiments presented herein, is incorporated by reference in its entirety. This may be better understood by reference to one or more of these drawings. [Brief explanation of the drawings]

[0017] [Figure 1] Schematic diagram showing a GMP-compliant protocol for isolating and expanding MSCs from umbilical cord tissue.

[0018] [Figure 2] Schematic showing a GMP-compliant protocol for expanding and generating pre-activated MSCs derived from umbilical cord tissue using a bioreactor.

[0019] [Figure 3] Data from large-scale expansion of MSCs from bone marrow and umbilical cord tissue in Terumo bioreactors.

[0020] [Figure 4] Flow cytometry analysis showing that umbilical cord tissue-derived MSCs express higher levels of stemness markers than bone marrow-derived MSCs.

[0021] [Figure 5A] Pre-activated CBt-MSCs exhibit a greater suppressive effect on T cell proliferation and activation than untreated CBt-MSCs. Suppression of CD4+ T cell proliferation mediated by pre-activated MSCs compared to untreated MSCs. [Figure 5B] Pre-activated CBt-MSCs exhibit a greater suppressive effect on T cell proliferation and activation than untreated CBt-MSCs. Suppression of CD4+ T cell activation mediated by pre-activated MSCs compared to untreated MSCs.

[0022] [Figure 6A] Preactivation of CBt-MSCs improves their immunosuppressive therapeutic potential. Preactivated CBt-MSCs exhibit a more immunosuppressive phenotype than preactivated bone marrow MSCs. [Figure 6B] Preactivation of CBt-MSCs improves their immunosuppressive therapeutic potential. Preactivation of MSCs increases the secretion of the immunoregulatory molecule TGS-6. [Figure 6C] Preactivation of CBt-MSCs improves their immunosuppressive therapeutic potential. Preactivation of CBt-MSCs induces the expression of immunomodulatory molecules on their surface, maximizing their therapeutic efficacy.

[0023] [Figure 7] Preactivation of CBt-MSCs with this cocktail of cytokines (TNF, IFN, IL1 and IL-17) has a higher therapeutic effect than commercially available preparations.

[0024] [Figure 8A] Fresh CBt-derived MSCs extended survival time in a xenograft-versus-host disease (GVHD) mouse model. Compared to GVHD controls, mice receiving fresh BM- or CBt-derived MSCs showed a significant increase in overall survival time. [Figure 8B]Fresh CBt-derived MSCs prolonged survival time in a xenograft-versus-host disease (GVHD) mouse model. Histopathological samples demonstrated a slight reduction in GVHD signs in the liver, spleen, and colon of treated (with BM- or CBT-MSCs) mice compared to GVHD controls. [Figure 8C] Fresh CBt-derived MSCs extended survival time in a xenograft-versus-host disease (GVHD) mouse model. Short-term biodistribution experiments using DiR immunofluorescently labeled MSCs injected into mice via the tail vein. CBt-MSCs showed significantly improved persistence over 72 hours compared to BM-MSCs.

[0025] [Figure 9A] Activation of CBt-MSCs revealed a unique profile with enhanced immunosuppressive properties. A heatmap of differentially expressed genes between resting and activated MSCs showed upregulation of 816 genes and downregulation of 383 genes in activated CBt-MSCs compared with resting CBt-MSCs. [Figure 9B] Activation of CBt-MSCs revealed a unique profile with higher immunosuppressive properties. Ingenuity Pathway Analysis (IPA) of genes evaluated for resting and activated CBt-MSCs revealed that cell activation induced the expression of genes related to several immunoregulatory pathways (e.g., T cell exhaustion, negative regulation of immune responses, IL-6 signaling, and induction of T cell apoptosis).

[0026] [Figure 10A]Activation enhanced the homing and biodistribution of CBt-MSCs in a GVHD xenograft mouse model. Heat maps of IPA analyses performed on RNA extracted from activated and quiescent CBt-MSCs revealed activation of several genes associated with extravasation and homing, including homing receptors and key adhesion molecules involved in adhesion and invasion, in activated CBtMSCs. [Figure 10B] Activation enhanced homing and biodistribution of CBt-MSCs in a GVHD xenograft mouse model. Heatmap of homing receptors, adhesion molecules, and invasion proteins (metalloproteinases) in activated CBt MSCs and quiescent MSCs assessed by flow cytometry. [Figure 10C] Activation enhanced the homing and biodistribution of CBt-MSCs in a mouse xenograft model of GVHD. After 72 hours of fluorescence analysis, activated CBt-MSCs remained in the mice for up to 3 days, longer than control CBt-MSCs. [Figure 10D] Activation enhanced the homing and biodistribution of CBt-MSCs in a mouse xenograft model of GVHD. After 72 hours of fluorescence analysis, activated CBt-MSCs remained in the mice for up to 3 days, longer than control CBt-MSCs. [Figure 10E] Activation enhanced the homing and biodistribution of CBt-MSCs in a mouse xenograft model of GVHD. Mouse tissues were collected 3, 48, and 72 hours after injection, and the mean radiant efficiency was calculated for each tissue. Compared to the control MSC group, the activated CBt-MSC group showed a tendency for higher fluorescence levels, as shown in Figure 10F for the lung, Figure 10G for the liver, and Figure 10H for the spleen. [Figure 10F]Activation enhanced the homing and biodistribution of CBt-MSCs in a mouse xenograft model of GVHD. Mouse tissues were collected 3, 48, and 72 hours after injection, and the mean radiant efficiency was calculated for each tissue. Compared to the control MSC group, the activated CBt-MSC group showed a tendency for higher fluorescence levels, as shown in Figure 10F for the lung, Figure 10G for the liver, and Figure 10H for the spleen. [Figure 10G] Activation enhanced the homing and biodistribution of CBt-MSCs in a mouse xenograft model of GVHD. Mouse tissues were collected 3, 48, and 72 hours after injection, and the mean radiant efficiency was calculated for each tissue. Compared to the control MSC group, the activated CBt-MSC group showed a tendency for higher fluorescence levels, as shown in Figure 10F for the lung, Figure 10G for the liver, and Figure 10H for the spleen. [Figure 10H] Activation enhanced the homing and biodistribution of CBt-MSCs in a mouse xenograft model of GVHD. Mouse tissues were collected 3, 48, and 72 hours after injection, and the mean radiant efficiency was calculated for each tissue. Compared to the control MSC group, the activated CBt-MSC group showed a tendency for higher fluorescence levels, as shown in Figure 10F for the lung, Figure 10G for the liver, and Figure 10H for the spleen.

[0027] [Figure 11A] Cryopreserved activated CBt-MSCs exhibited similar viability, phenotype, and efficacy in regulating T cell activation compared to freshly activated CBt-MSCs. Representative FACS plots of CBt-MSC viability measured by flow cytometry using Annexin V and propidium iodide assays. [Figure 11B] Cryopreserved activated CBt-MSCs showed similar viability, phenotype, and efficacy in regulating T cell activation compared to freshly activated CBt-MSCs. Representative histograms of T cell proliferation CFSE assays showing overall suppression of T cells activated with CD3 / CD28 beads at all different ratios. [Figure 11C] Cryopreserved activated CBt-MSCs displayed similar viability, phenotype, and efficacy in regulating T cell activation compared to freshly activated CBt-MSCs. Representative FACS plots of activated MSC phenotype using fresh or frozen / thawed cells, showing persistence of immunosuppressive factor expression.

[0028] [Figure 12A] Cryopreserved activated CBt-MSCs extended overall survival time and reduced GVHD toxicity. Figure 12A summarizes in vivo experiments using groups of mice (n = 8 mice per group). Survival curves for untreated (GVHD control), recipients of non-activated CBt-MSCs, and recipient-activated CBt-MSCs. The data demonstrate the survival benefit of activated CBt-MSCs in recipients compared with non-activated MSCs or controls. [Figure 12B] Cryopreserved activated CBt-MSCs extended overall survival and reduced GVHD toxicity. Figure 12B summarizes in vivo experiments using groups of mice (n = 8 mice per group). Weight fluctuations show less weight loss in recipients of activated CBt-MSCs compared to the other two groups. [Figure 12C] Cryopreserved activated CBt-MSCs extended overall survival time and reduced GVHD toxicity. Figure 12C summarizes the in vivo experiments using groups of mice (n=8 mice per group). The mean GVHD scores again show lower GVHD in the activated CBT-MSC group. [Figure 12D] Cryopreserved activated CBt-MSCs prolonged overall survival and reduced GVHD toxicity.Portal liver inflammation compared among the three groups of mice at the end point. [Figure 12E]Cryopreserved activated CBt-MSCs extended overall survival and reduced GVHD toxicity. Comparison of hematological tests between untreated mice (control), mice treated with quiescent CBt-MSCs, and mice treated with activated (activated) MSCs. These blood tests included WBC count, MCV, MCHC, hematocrit, hemoglobin, platelet count, RBC count, MCH, RDW, albumin, alkaline phosphatase, potassium, LDH, AST, glucose, ALT, phosphorus, and total protein. Results show improved platelet count, glucose, WBC count, and liver function (ALT, AST) in the activated MSC-treated group compared with the control or non-activated MSC groups. [Figure 12F] Cryopreserved activated CBt-MSCs extended overall survival and reduced GVHD toxicity. Results of cytokine levels in the blood of mice revealed that both activated and non-activated CBt-MSCs reduced the presence of inflammatory cytokines compared to control mice. [Figure 12G] Cryopreserved activated CBt-MSCs extended overall survival and reduced GVHD toxicity. Percentage of human CD45 in the blood of mice on day 24. The left panel shows representative FACS plots for each group, and the right panel shows bar plots with statistical comparisons compared to the control group (untreated). **p-value < 0.01, ****p-value < 0.0001 indicate fewer human CD45+ cells in the blood of both MSC recipient groups, with activated MSCs representing fewer than non-activated MSC recipients. DETAILED DESCRIPTION OF THE INVENTION

[0029] DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS Bone marrow-derived MSCs have been used for many years to treat refractory graft-versus-host disease (GVHD). It has been used in the treatment of ischemic stroke, cardiovascular disease, inflammatory bowel disease and acute respiratory distress syndrome, and more recently in the treatment of It has been used in regenerative medicine situations, including distress syndrome. Blood has been extensively evaluated, but compared with bone marrow, MSC generation is highly variable and insufficient. Therefore, certain embodiments of the present disclosure provide: A method for expanding MSCs derived from umbilical cord tissue is provided. The method comprises: Good manufacturing practices for the production of large quantities of CBt-derived MSCs in vitro It provides a robust method that is Good Manufacturing Practice (GMP) compliant.

[0030] In particular, the present method for expanding MSCs significantly outperforms those produced without preactivation. The method may include a pre-activation step to generate CBt-derived MSCs that are suppressive for the activation of CBt. reported that MSCs are stimulated with cytokines such as TNFα, IFNγ, IL-1β, and IL-17. Thus, the method can be implemented in a novel GMP-compliant system. Using this system, CBt-derived MSCs can be produced in larger quantities than BM-derived MSCs in a shorter time. Therefore, CBt-MSCs can be produced more cheaply and efficiently than BM-derived MSCs.

[0031] In this study, pre-activated and expanded MSCs produced more pluripotent stem cells than BM-derived MSCs. These stem cell markers were found to express "stem cell" markers. When pre-activated and expanded, MSCs are able to grow in various tissues, including the brain, heart, gastrointestinal tract, and lungs. This may provide more specific regeneration of vital organs. The MSCs also contribute to the development of inflammation in GVHD, including the gastrointestinal tract and skin, as well as the immune system. In regenerative medicine situations where acute inflammation occurs in the brain and heart, Higher levels of immunosuppressive factors and chemokine receptors (VEGF, HLA) may contribute to The cells express the following: IL-G, PGE, CXCR4, IL-10, and TGFβ. Activated MSCs generated by this method inhibit several immune regulatory pathways, e.g., T cell exhaustion, granulocyte adhesion and extravasation, antigen presentation pathway, negative regulation of immune responses, Notch signaling Positive regulation of lymphocyte apoptosis, agranulocyte adhesion and vasculogenesis Transmigration, regulation of cellular response to hypoxia, TGFβ signaling, NFKβ signaling , IL-6 signaling, iNos and eNos signaling 1, STAT4 and P Positive regulation of I3K signaling and genes involved in the induction of T cell apoptosis Activated MSCs were also found to induce the expression of CBtMSCs. Homing receptors and key adhesion molecules involved in adhesion and invasion in Several genes involved in extravasation and homing, such as GLG1, V CAM1, CXCR4, ICAM1, CSF3, CXCL3, CXCL8, SELPG, STAT1, IFITT3, ISG15, STAT2, MX1, OAS1, IFI6, J AK2, TAP1, IFI35, IFITM1, PSM89, IRF1, IFITM3, PTPN2, RELA, IFNAR2, HSP90AA1, JUN, ARNT, HIF1 and CUL2 activation.

[0032] By using this system, it is possible to inject tissue into patients in accordance with GMP standards. Large numbers of clinical-grade CBt-derived MSCs can be generated in a functionally closed system. Thus, the highly immunosuppressive MSCs provided herein can be used to treat, for example, inflammatory conditions, For example, for the treatment of GVHD and autoimmune diseases, as well as acute ischemic stroke, myocardial Injury, acute respiratory distress syndrome (ARDS), and inflammatory bowel disease are some of the conditions in regenerative medicine. In certain circumstances, methods for use are further provided herein.

[0033] I. Definition As used herein, "essentially free" with respect to a particular component means that Certain components are not intentionally formulated into the composition and / or are not intended to be contaminants. It is used herein to mean the absence of even a trace amount. Therefore, the total amount of a particular component resulting from any unintentional inclusion of that component in a composition is , less than 0.05%, preferably less than 0.01%. Most preferred are compositions in which the amount of the component is undetectable.

[0034] As used herein, "a" or "an" may mean one or more. When used in a clause, the words "a" or "an" are used in conjunction with the word "including." It can mean one or more than one.

[0035] Use of the term "or" in the claims refers to alternatives only, unless expressly indicated to be so. or used to mean "and / or" unless the alternatives are mutually exclusive. However, the present disclosure supports the definition that refers to only alternatives and "and / or." As used herein, "another" means at least a second or more. The term "about" refers to the stated value plus or minus 5%. .

[0036] The terms "mesenchymal stem cells," "mesenchymal stromal cells," or "MSCs" are used herein. When used in combination with other stem cells, they are pluripotent somatic stem cells derived from the mesoderm, particularly connective tissue, bone marrow stroma, etc. , self-renewal capacity to generate progeny cells with diverse phenotypes, including adipocytes, dermis, and muscle MSCs are pluripotent somatic stem cells that have the ability to differentiate and differentiate themselves. CD19, CD45, CD14 and HLA-DR were negative, and the markers CD105, Cell marker expression profiles characterized by positivity for CD106, CD90, and CD73 MSCs can be isolated from any type of tissue. M may be isolated from bone marrow, adipose tissue, umbilical cord, or peripheral blood. SCs are stem cells derived from bone marrow.

[0037] The term "functional closure" means that the entire system is sealed or all access points to the collection system are closed. A sterile barrier filter is provided at the connection point to ensure fluid sterility. It refers to a sealed system.

[0038] The term "bioreactor" refers to a process in which nutrients are provided to cells in a sterile, closed system, Large-scale cell culture, which removes metabolic products and provides a physiochemical environment conducive to cell growth. In certain embodiments, biological and / or biochemical processes include: Under monitored and controlled environmental and operating conditions, e.g., pH, temperature, pressure This occurs under the influence of energy, nutrient supply and waste removal. A basic class of bioreactors suitable for use in the production of ethanol includes hollow fiber bioreactors. .

[0039] The term "hollow fiber" refers to a fiber that delivers nutrients (in solution) to cells contained within a bioreactor. and waste materials (e.g., from cells contained within a bioreactor) for use in reaching It contains pores of defined size, shape and density for use in removing ions from a solution. In this disclosure, hollow fibers are intended to include any hollow structure (of any shape) that can absorb Fibers may be constructed from absorbent or non-absorbent materials. Fibers include, but are not limited to, tubular structures. Not determined.

[0040] "Immune disorder," "immune-related disorder," or "immune-mediated disorder" means a disorder that affects the onset or progression of a disease. Immune-mediated disorders include: Autoimmune disorders, allograft rejection, graft-versus-host disease, and inflammatory and allergic The following conditions can be mentioned.

[0041] An "autoimmune disease" is a condition in which the immune system reacts to antigens that are part of the normal host (i.e., self-antigens). an immune response (e.g., B cell or T cell response) against the Autoantigens can be derived from host cells or can be transmitted through the body. Commensal organisms, such as microorganisms (known as commensals), that normally colonize mucosal surfaces It can be derived from a living organism.

[0042] The term "graft-versus-host disease (GVHD)" refers to a common and serious complication of bone marrow transplantation. refers to the immunologically competent transfer of donated tissue to the transplant recipient's own tissue. There is a lymphocyte response. GVHD occurs when stem cells from related or unrelated donors are transplanted. This is a complication that can occur in any implant that uses or includes In some embodiments, the GVHD is chronic GVHD (cGVHD), and in some embodiments, The VHD is acute GVHD (aGVHD).

[0043] A "parameter of an immune response" is any specific measurable aspect of an immune response, These include cytokine secretion (IL-6, IL-10, IFN-γ, etc.), chemokines, secretion, migration or cell accumulation, immunoglobulin production, dendritic cell maturation, regulatory These include, but are not limited to, activity, number of regulatory B cells, and proliferation of any cell of the immune system. Another parameter of the immune response is the structural damage of any organ resulting from the immunological attack. Those skilled in the art can measure these parameters using known laboratory assays. In one non-limiting example, an increase in cell proliferation or any one of the following data can be readily determined: To evaluate 3 3H-thymidine incorporation can be assessed. A "substantial" increase is a significant increase in this parameter compared to the control. Non-limiting examples of qualitative increases include an increase of at least about 50%, an increase of at least about 75%, and the like. increase, increase by at least about 90%, increase by at least about 100%, increase by at least about 200% an increase of at least about 300% and an increase of at least about 500%. Inhibition or reduction of a parameter of the immune response is determined by the increase or decrease in this parameter compared to a control. Non-limiting examples of a substantial reduction include a reduction of at least about 50%; at least about a 75% decrease, at least about a 90% decrease, at least about a 100% decrease, at least about a 200% decrease, at least about a 300% decrease, and at least about a 500% decrease A statistical test, such as a non-parametric ANOVA or T-test, is used to By comparing the percentage of samples that respond with a second agent, Differences in the magnitude of the response induced by one agent can be compared. In the example, p ≤ 0.05 is significant and confirms the observed increase or decrease in any parameter. This suggests that the probability that the rate fluctuations are due to a variability of the variability is less than 5%. Those skilled in the art will recognize other statistical analyses that may be useful. The assay can be easily identified.

[0044] "Treating" a disease or condition or treating a disease or condition means alleviating the symptoms of the disease. or a protocol that may involve administering one or more drugs to a patient for the purpose of alleviating symptoms. The desired effects of treatment include slowing the progression of the disease, improving the condition, Remission or alleviation of symptoms and remission or improvement of prognosis. It can occur before as well as after the signs or symptoms of a condition appear. "Placing" or "treating" a disease or unwanted condition is not "preventing" or "preventing" a disease or unwanted condition. Furthermore, "treat" or "treatment" can include the complete alleviation or amelioration of signs or symptoms. It does not require relief, it does not require a cure, and in particular it only has a marginal effect on the patient. Includes protocols.

[0045] The term "therapeutic effect" or "therapeutically effective" as used throughout this application means Refers to something that promotes or improves the well-being of a subject in relation to medical treatment for a condition This includes reducing the frequency or severity of signs or symptoms of a disease, but For example, cancer treatment includes, for example, reducing tumor size, reducing tumor invasiveness, and the like. Treatment of cancer may include administering to a subject with cancer, reducing the rate of cancer growth, or preventing metastasis. It can also refer to an extension of survival time.

[0046] "Subject" and "patient" refer to a human or non-human, e.g., a primate, mammal, and It refers to a vertebrate. In certain embodiments, the subject is a human.

[0047] As used broadly herein, "pharmaceutically acceptable" means any substance that is pharmaceutically acceptable according to sound medical judgment. within the limits of the range of Human and animal tissues, organs, and organs without other problems or complications that are commensurate with the fit / risk ratio Compounds, materials, compositions and compositions suitable for use in contact with organs and / or body fluids Refers to the drug and / or dosage form.

[0048] "Pharmaceutically acceptable salts" are those which are pharmaceutically acceptable as defined above and It also refers to salts of the compounds disclosed herein that possess the desired pharmacological activity. Salts can be prepared from inorganic acids (e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc.); or organic acids. (e.g., 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, 2-naphtho Sulfonic acid, 3-phenylpropionic acid, 4,4'-methylenebis(3-hydroxybenzoate) -2-ene-1-carboxylic acid), 4-methylbicyclo[2.2.2]oct-2-ene- 1-carboxylic acids, acetic acids, aliphatic monocarboxylic acids and dicarboxylic acids, aliphatic sulfuric acids, Aromatic sulfuric acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, carbonic acid, cinnamic acid, Citric acid, cyclopentanepropionic acid, ethanesulfonic acid, fumaric acid, glucoheptone Acid, gluconic acid, glutamic acid, glycolic acid, heptanoic acid, hexanoic acid, hydroxynaphthalene Phthoic acid, lactic acid, lauryl sulfate, maleic acid, malic acid, malonic acid, mandelic acid, methane Sulfonic acid, muconic acid, o-(4-hydroxybenzoyl)benzoic acid, oxalic acid, p-chloro C12-13 alkylbenzenesulfonic acid, phenyl-substituted alkanoic acids, propionic acid, p-toluenesulfonic acid Acid, pyruvic acid, salicylic acid, stearic acid, succinic acid, tartaric acid, tertiary butyl acetate, Pharmaceutically acceptable salts include acid addition salts formed with methyltrimethylacetic acid, etc. A base bond that can be formed when an acidic proton present can react with an inorganic or organic base. Acceptable inorganic bases include sodium hydroxide, sodium carbonate, Acceptable hydroxides include potassium hydroxide, aluminum hydroxide, and calcium hydroxide. Examples of organic bases that can be used include ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, etc. Any salt of the present invention may be used as a whole. The specific anion or cation forming a part of the salt may be used as long as it is pharmacologically acceptable. It should be recognized that the amount of the compound is not critical. Pharmaceutically acceptable salts and their derivatives are also included. Further examples of methods of preparation and use can be found in the Handbook of Pharmacy tical Salts:Properties,and Use(PHStahl & CGWermuth eds.,Verlag Helvetica Chi This is presented in the Journal of Applied Physics, Vol. 1, No. 1, pp. 11

[0049] A "pharmaceutically acceptable carrier," "drug carrier," or simply "carrier" refers to a Drugs formulated with active ingredient drugs involved in the transport, delivery and / or transportation of chemical substances. Drug carriers are substances that are physiologically acceptable. Drug carriers can be used to improve, for example, drug bioavailability. to regulate the activity of the drug, to reduce drug metabolism and / or to reduce drug toxicity These can be used to improve drug delivery and efficacy, including release technologies. Some drug carriers can enhance the effectiveness of drug delivery to specific target sites. Examples of carriers Examples include liposomes, microspheres (e.g., poly(lactic-co-glycolic acid) (composed of nanofibers), albumin microspheres, synthetic polymers, nanofibers, proteins -DNA complexes, protein conjugates, erythrocytes, virosomes and dendrimers. do.

[0050] The term "culturing" refers to maintaining, differentiating and / or culturing cells in vitro in a suitable medium. "Concentrated" refers to the tissue in which a cell resides within an organism. Contains cells that are present as a percentage of total cells higher than the percentage seen in "composition" means a composition comprising

[0051] "Isolated" biological components (e.g., parts of hematological material, e.g., blood constituents) A biological component is one whose constituent is substantially isolated from other biological constituents of the organism in which it occurs in nature. An isolated cell refers to a cell that is isolated from the organism in which it occurs in nature. A cell that has been substantially separated or purified from other biological components of an organism.

[0052] As used herein, the term "substantially" means at least 80% of the desired component. %, more preferably 90% of the desired component, or most preferably 10% of the desired component. In some embodiments, the composition is The article contains at least 80%, 82%, 84%, 86%, 88%, 90%, or Including 91%, 92%, 93%, 94%, 95%, 96%, 97% or 98%.

[0053] II. Mesenchymal stromal cells The present disclosure relates to the expansion of MSCs. The MSCs used in the culture may be any stem cell. Cell origin, e.g., umbilical cord, umbilical cord blood, placenta, embryonic stem cells, adipose tissue, bone marrow or other tissue specific These samples may include fresh samples, frozen samples, or cells derived from allogeneic mesenchyme. In certain embodiments, the MSCs are obtained from umbilical cord tissue, and These methods for expanding CBt-derived MSCs are derived. In certain embodiments, MS C are human MSCs, which can be autologous or allogeneic.

[0054] A. Isolation of MSCs from Umbilical Cord Tissue In one embodiment, the MSCs are isolated in the presence of one or more enzymatic activities. A wide range of digestive enzymes are known in the art for use in isolating cells from tissues. , which contain enzymes that are considered to be less digestive (e.g., deoxyribonuclease and dispase, a neutral protease) to enzymes that are considered to be highly digestive ( Currently preferred are enzymes ranging from mucolytics to steroids (e.g., papain and trypsin). Mucolytic enzyme activity, metalloprotease, neutral protease, serine Proteases (e.g., trypsin, chymotrypsin, or elastase) and deoxygenases More preferred are metalloproteases and neutral proteases. and mucolytic activity. The enzyme may be isolated in the presence of one or more of the following activities: malidase and dispase.

[0055] Umbilical cord tissue can be obtained from mammals, such as humans. In particular, umbilical cord tissue can be obtained from elective uterine transplants. Umbilical cord tissue is obtained from full-term newborns after rectal section. It may be transported in plasmalyte, which contains acetone and other compounds. The umbilical cord tissue is then split and thawed, e.g., for 30 to 90 minutes, particularly 70, 71, 72, 73 , 74, 75, 76, 77, 78, 79, or 80 minutes at 30-40°C, especially 37°C. The cells may be incubated at 4°C for 1 hour.

[0056] The umbilical cord tissue may be purified using the methods described herein, including collagenase, hyaluronidase, and / or DNAse. Collagenase may be dissociated in the enzyme cocktail provided herein. The umbilical cord tissue was then purified using GentleMACS Oc Dissociation devices such as the Miltenyi Dissociator The cell suspension can then be filtered, washed, and resuspended in medium. , e.g., 10% platelet lysate with pen-strep, L-glutamine, heparin The cells were resuspended in alpha-MEM medium (complete medium) containing 100% ethanol and seeded into a T175 flask. The MSCs are then cultured until they are about 80% confluent. The cells were harvested and expanded to approximately 80% confluence in complete medium without antibiotics. The culture may be for about 6 to 8 days, particularly about 7 days.

[0057] Cell culture surfaces for MSC culture include standard tissue culture vessels and two-dimensional surfaces (see culture flasks, bags, culture bottles or multi-well dishes Examples of such compounds include, but are not limited to, cereals containing gluten.

[0058] By providing the above growth conditions, the culture medium, supplements, and atmospheric conditions for the cells can be This allows for a wide range of temperature and relative humidity options. The preferred temperature is 37°C. However, the temperature may vary depending on other culture conditions and the desired use of the cells or culture. , may be in the range of about 35°C to 39°C.

[0059] Those skilled in the art will appreciate that the supplements to the growth medium may vary and that the growth medium may be It may be modified in any way known in the art and optimized for specific reasons. Furthermore, the cells can be grown in a chemically defined medium in the absence of serum supplementation. They can also grow in many other media, including those listed below. Some such media are listed below. In addition to the conventional culture and maintenance of the above cells, the differentiation potential of such pote Many other methods are available to influence the differentiation of nt) cells into specific cell types or specific cell progenitors. Such media are known in the art. Those skilled in the art will appreciate that these media are useful for many purposes and will be familiar with the present invention. Although included within the scope of the invention, it is not necessarily preferred for routine cultivation and expansion. You will realize that it isn't.

[0060] In addition to the flexibility of these cells to the culture medium, they can grow under a variety of environmental conditions. In particular, the cells can be grown under a wide range of atmospheric conditions. The atmosphere is in the range of 5% to about 20% O2 or higher. Under conditions, typically in the presence of about 5% CO2 and in the balance of the atmosphere as nitrogen, Those skilled in the art will appreciate that the cells described above grow and expand well in various media. A wider range of conditions may be tolerated, and optimization for specific purposes may be appropriate. will recognize that.

[0061] Cryopreservation of cells prior to culture or cryopreservation of expanded cells as disclosed herein can include: This can be done according to known methods. For example, the cells are frozen in a "freezing medium", e.g., 10% dimethyl sulfoxide (DMSO) with or without 5-10% glycerol In the culture medium, for example, about 1 to 2 × 10 6 The cells can be suspended at a density of 1000 cells / ml. The mixture may be dispensed into glass or plastic vials, which are then sealed and programmed. The freezing rate can be adjusted by adding a 1000 ml sample of frozen food to the freezing chamber of a passive or passive freezer. can be determined empirically. For example, a freezing point that produces a temperature change of about -1°C / min due to the heat of fusion is A freezing program can be used. Once the vials containing the cells reach -80°C, they are lysed. The body may be transferred to a nitrogen storage area.

[0062] In some embodiments, freshly isolated cells from any stem cell source are cryopreserved. A cell bank may be constructed by thawing a portion of the cell bank, and the cell bank may be extracted as needed. The cells may then be thawed quickly, e.g., using a thawing machine. For example, this can be done by transferring the vial from liquid nitrogen to a 37°C water bath. The contents of the thawed vial were immediately transferred to nutrient medium. The cells can be transferred under sterile conditions to a culture vessel containing an appropriate medium, such as a medium containing 2000 kJ / ml of erythrocytes. At an appropriate density, cells may be examined daily to detect proliferation, for example using an inverted microscope. Once reached, they can be subcultured immediately.

[0063] If desired, cells can be removed from the cell bank and cultured in vitro, e.g., as a 3D foot pad. In situ culture or in vivo, for example, where tissue reconstruction or repair is required. By administering the cells directly to the affected area, they can be used to generate new stem cells or tissue. As described herein, the expanded MSCs of the present disclosure may be prepared by culturing cells that are initially used to reconstruct or repair tissue in a subject isolated from the subject's own tissue Alternatively, the expanded MS cells disclosed herein may be used (i.e., autologous cells). C is a ubiquitous donor cell for reconstructing or repairing tissue in any subject. can be used as a heterologous cell (i.e., a heterologous cell).

[0064] B. Pre-activation of MSCs MSCs isolated from umbilical cord tissue were then cultured in the presence of cytokines for preactivation. The cytokines may be TNFα, IFNγ, IL-1β and / or or IL-17, in particular TNFα, IFNγ, IL-1β and IL-17. The pre-activation step is carried out for about 12 to 24 hours, e.g., 13, 14, 15, 16, 17, It may be 18 or 19 hours, particularly 16 hours. TNFα, IFNγ and / or IL-1 -1β is used at a concentration of 5 to 15 ng / mL, e.g., 6, 7, 8, 9, 10, 11, 12, 1 IL-17 may be 20 to 40 ng / mL, 3 or 14 ng / mL, particularly about 10 ng / mL. ng / mL, for example, 25, 30 or 35 ng / mL, particularly about 30 ng / mL It can exist.

[0065] C. Expansion of MSCs in Bioreactors The MSCs can then be expanded in a functional closed system such as a bioreactor. Expansion can be performed in a Quantum Bioreactor (Terumo), e.g., 4 It may be performed for up to 10 days, especially 5-6 days.

[0066] Bioreactors include static bioreactors, stirred flask bioreactors, rotating wall bioreactors, Includes vessel bioreactors, hollow fiber bioreactors, and direct perfusion bioreactors. In bioreactors, cells can be grouped according to general categories, including: They can be floating or seeded and immobilized on porous 3D scaffolds (hydrogels). It may also be used.

[0067] Hollow fiber bioreactors can be used to improve mass transfer during cultivation. A hollow fiber bioreactor is a 3D cell culture system based on hollow fibers. , with a typical molecular weight cut-off (MWCO) range of 10-30 kDa. These hollow fiber membranes are bundled together to form a tubular porous membrane. Encased within a recarbonate shell to form a hollow fiber bioreactor cartridge These cartridges often have an inlet and an outlet, and are filled with hollow fibers. The two compartments are the intracapillary (IC) space and the extracapillary (EC) space around the hollow fiber. It is a nt.

[0068] Thus, for the present disclosure, the bioreactor may be a hollow fiber bioreactor. In hollow fiber bioreactors, cells are embedded within the lumen of the fibers, and the cells are dispersed outside the lumen. The space may be perfused with medium, or gas and medium may be perfused through the hollow fibers. A hollow fiber bioreactor suitable for the present disclosure may be provided to allow cells to grow within the extraluminal space. Actors are known in the art and include Caridian (Terumo )BCT Quantum Cell Expansion System may be mentioned. However, it is not limited to this.

[0069] Hollow fibers are suitable for nutrient delivery and waste removal in bioreactors The hollow fibers can be of any shape, for example, circular and tubular or concentric. It may be in the shape of a circular ring. The hollow fibers may be composed of absorbable or non-absorbable membranes. For example, suitable hollow fiber components include polydioxanone, polylactide, polyglycol Lactin, polyglycolic acid, polylactic acid, polyglycolic acid / trimethylene carbonate , cellulose, methylcellulose, cellulose polymers, cellulose esters, regenerated cellulose Examples include cellulose, Pluronic®, collagen, elastin, and mixtures thereof. It can be obtained.

[0070] The bioreactor may be primed prior to seeding with cells. Priming may involve flushing the bioreactor with a buffer such as PBS. This may include coating with an extracellular matrix protein such as fibronectin. The bioreactor can then be washed with medium such as alpha MEM.

[0071] The above MSCs were cultured in a bioreactor at approximately 100-1,000 cells / cm. 2 , for example, about 1 50 cells / cm 2 , about 200 cells / cm 2 , about 250 cells / cm 2 , about 300 cells / cm 2 , e.g., about 350 cells / cm 2 , e.g., about 400 cells / cm 2 , for example, about 450 cells / cm 2 , e.g., about 500 cells / cm 2 , e.g., about 550 cells / cm 2 ,for example , about 600 cells / cm 2 , e.g., about 650 cells / cm 2 , e.g., about 700 cells / cm 2 , e.g., about 750 cells / cm 2 , e.g., about 800 cells / cm 2 , for example, about 850 cells / cm 2 , e.g., about 900 cells / cm 2 , e.g., about 950 cells / cm 2 or about 1000 cells / cm 2 In particular, the cells can be seeded at a density of about 400-500 cells / cm 2 cell density, e.g., about 450 cells / cm 2 It can be sown in

[0072] The total number of cells seeded into the bioreactor is approximately 1.0 × 10 6 ~Approx. 1.0×10 8 Thin Cells, e.g., about 1.0 x 10 6 ~5.0.0×10 6 , 5.0×10 6 ~1.0×10 7 , 1.0×10 7 ~5.0×10 7 , 5.0×107 ~1.0×10 8 It may be a cell. In certain embodiments, the total number of cells seeded into the bioreactor is about 1.0 x 10 7 ~ Approximately 3.0×10 7 , for example, about 2.0 x 10 7 It is a cell.

[0073] The cells may be seeded in any suitable cell culture medium, many of which are commercially available. Exemplary media include DMEM, RPMI, MEM, and Media199. In one embodiment, the medium is alpha MEM medium, In particular, alpha MEM supplemented with L-glutamine. The above may be supplemented: growth factors, cytokines, hormones or B27, antibiotics, vitamins In particular, the medium may be serum-free.

[0074] In some embodiments, the cells may be incubated at room temperature. The atmosphere may be humidified and may be about 5% CO and about 1% O. In some embodiments, the CO2 concentration may range from about 1-20%, 2-10%, or 3-5%. In some embodiments, the O2 concentration is about 1-20%, 2-10%, or 3-5%. The range may be:

[0075] III.How to use The expanded MSCs of the present disclosure have broad applications in the treatment and repair of disease and injury. The expanded MSCs of the present disclosure are useful for tissue repair, reconstruction and regeneration, as well as gene delivery. The MSCs disclosed herein are useful in many therapeutic applications, including the development of lineage-committed Both age-committed and uncommitted cells Both cell types may be used together to achieve multiple therapeutic goals. In some embodiments, the present invention can be used simultaneously. The expanded MSCs shown can be used directly as stem cell grafts or can be used in combination with other methods described above. As mentioned above, they can be used as stem cell grafts in suspension or on cell culture support scaffolds. .

[0076] Certain embodiments of the present disclosure are directed to treating or preventing inflammatory or immune-mediated disorders. The present invention relates to methods for using MSCs to treat cancer, including the treatment of cancer cells, including the treatment of cancer cells. and administering a therapeutically effective amount of MSCs to a subject to treat an inflammatory disorder or Treating or preventing an immune-mediated disorder is included.

[0077] MSCs produced according to this method have many applications, including experimental and therapeutic uses. In particular, such cell populations may be used to treat unwanted or inappropriate immune responses. It is envisioned that this will be extremely useful in suppressing responses.

[0078] In one embodiment, a subject suffering from an autoimmune or inflammatory disease is administered the In one embodiment, the subject is administered MSCs as provided herein. Non-limiting examples of autoimmune diseases include alopecia areata, ankylosing spondylitis, and anti-inflammatory drugs. Phospholipid syndrome, autoimmune Addison's disease, autoimmune diseases of the adrenal gland, autoimmune hemolytic anemia blood, autoimmune hepatitis, autoimmune oophoritis and orchitis, autoimmune thrombocytopenia Behçet's disease, bullous pemphigoid, cardiomyopathy, celiac polydermatitis spate-dermatitis), chronic fatigue immune deficiency syndrome (CFIDS), chronic Inflammatory demyelinating polyneuropathy, Churg-Strauss syndrome, cicatricial pemphigoid, CR EST syndrome, cold agglutinin disease, Crohn's disease, discoid lupus, essential mixed cryoglobulinemia Hemoglobinemia, fibromyalgia-fibromyositis, glomerulonephritis, Graves' disease, Guillain-Barre, Hashimoto's thyroiditis , idiopathic pulmonary fibrosis, idiopathic thrombocytopenic purpura (ITP), IgA neuropathy, juvenile Arthritis, lichen planus, lupus erythematosus, Meniere's disease, mixed connective tissue disease, multiple sclerosis, Type 1 diabetes or immune-mediated diabetes, myasthenia gravis, nephrotic syndrome (e.g., minimally invasive nephropathy, focal glomerulosclerosis or membranous nephropathy), pemphigus vulgaris, pernicious anemia, polyarterial nodular syndrome inflammation, polychondritis, polyglandular syndrome, polymyalgia rheumatica, polymyositis and dermatomyositis, Primary agammaglobulinemia, primary biliary cirrhosis, psoriasis, psoriatic arthritis, Raynaud's phenomenon , Reiter's syndrome, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, Tiff-Mann syndrome, systemic lupus erythematosus, lupus erythematosus, ulcerative colitis, bud Uveitis, vasculitis (e.g., polyarteritis nodosa, Takayasu's arteritis, temporal arteritis / giant cell arteritis) These include dermatitis herpetiformis (or dermatitis herpetiformis vasculitis), vitiligo, and Wegener's granulomatosis. Thus, some examples of autoimmune diseases that can be treated using the methods disclosed herein are: These include multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, type 1 diabetes, and Crohn's disease. diseases such as ulcerative colitis, myasthenia gravis, glomerulonephritis, ankylosing spondylitis, vasculitis, or psoriasis. The subject may also have an allergic disorder, such as asthma.

[0079] In yet another embodiment, the subject is a recipient of a transplanted organ or stem cells. The expanded MSCs are then used to prevent and / or treat rejection. In some embodiments, the subject has or develops graft-versus-host disease. GVHD is a risk factor for transplants that use stem cells from related or unrelated donors. GVHD is a complication that can occur with any transplant, including those with liver cirrhosis. There are two types of GVHD: acute and chronic. Acute GVHD appears within the first 3 months after transplant. Signs of acute GVHD include: Symptoms include a reddish rash on the hands and feet, which may be followed by peeling or blisters on the skin. Acute GVHD can spread with the formation of ulcers and become more severe. The intestines may also be affected, causing muscle cramps, nausea and diarrhea. Yellowing of the eyes (jaundice) suggests that acute GVHD is affecting the liver. Stage D is graded based on its severity: Stage / Grade 1 is mild; Grade 1 / Grade 2 is severe. Chronic GVHD may develop 3 months or later after transplant. Symptoms of chronic GVHD are similar to those of acute GVHD, but in addition, It can also affect the mucous glands in the eyes, the salivary glands in the mouth, and the glands that lubricate the stomach wall and intestines. Examples of transplanted organs include organ grafts, e.g., kidney, liver, skin, pancreas, lung, and / or or heart, or cell grafts, e.g., islets, hepatocytes, myoblasts, bone marrow or hematopoietic The transplant may be a composite transplant, e.g., a facial transplant. The MSCs may be administered before, simultaneously with, or after transplantation. In some embodiments, the MSCs are administered prior to transplantation, for example, at least 1 hour prior to transplantation. , at least 12 hours in advance, at least 1 day in advance, at least 2 days in advance, at least 3 days in advance, At least 4 days in advance, at least 5 days in advance, at least 6 days in advance, at least 1 week in advance, at least administered at least 2 weeks, at least 3 weeks, at least 4 weeks, or at least 1 month prior to the In one specific, non-limiting example, administration of a therapeutically effective amount of MSCs is performed 3 to 5 days prior to transplantation. will be held.

[0080] In a further embodiment, administration of a therapeutically effective amount of MSCs to a subject results in a Thus, the method involves administering a therapeutically effective amount of MSCs to a subject. to inhibit the inflammatory process. Examples of inflammatory disorders include asthma, encephalitis, and inflammatory bowel disease, chronic obstructive pulmonary disease (COPD), allergic disorders, septic shock, pulmonary tuberculosis fibrosis, undifferentiated spondyloarthropathy, undifferentiated arthropathy, arthritis, inflammatory osteolysis, and chronic viral infections Examples of chronic inflammation include, but are not limited to, chronic inflammation resulting from infectious or chronic bacterial infections. The methods disclosed herein can also be used to treat allergic disorders. do.

[0081] Administration of MSCs is useful whenever immunosuppression or inhibition of inflammation is desired, for example, in the treatment of diseases. or whenever the first signs or symptoms of inflammation appear. Signs or symptoms of the disease may be, for example, pain, edema, elevated body temperature, or the function of the affected organ. For example, in kidney transplant rejection, blood In GVHD, there may be a rash and asthma, whereas serum creatinine levels may be elevated. There may be shortness of breath and wheezing.

[0082] Administration of MSCs can also be used to prevent immune-mediated diseases in a subject of interest. For example, MSCs can be administered to a prospective transplant recipient prior to transplantation. In another example, MSCs are administered to a subject undergoing allogeneic bone marrow transplantation without T cell depletion. In a further example, MSCs can be administered to a subject with a family history of diabetes. In the present study, MSCs are administered to subjects with asthma to prevent asthma attacks. In some embodiments, a therapeutically effective amount of MSCs is administered to a subject prior to symptoms. administration of EGFR-1400 was associated with a lower incidence of subsequent immunological events compared with patients receiving other therapies that did not include regulatory cells. or a reduction in the incidence or severity of symptoms (e.g., asthma attacks) or patient survival time. This can result in improvements in:

[0083] The effectiveness of treatment can be measured by a number of methods known to those skilled in the art. uses white blood cell count (WBC) to measure the responsiveness of a subject's immune system. The number of white blood cells in the body is measured in a blood sample of a subject using methods well known in the art. The normal white blood cell count is about 4,500 to 5,000. A white blood cell count lower than this is a sign of an immune disorder in the subject. May indicate a state of inhibition.

[0084] In another embodiment, immunosuppression in a subject is measured using T lymphocyte counts. Using methods well known in the art, white blood cells in a blood sample from a subject are isolated from other blood cells. T lymphocytes are isolated from the cells by standard methods in the art, such as immunofluorescence or immunohistochemistry. or FACS to distinguish them from other white blood cells. A decrease in the number of T cells (or in a specific population) before treatment can be used as a measure of immunosuppression. A decrease in the number of T cells or a specific population of T cells compared to the total number of T cells in the blood. This can indicate that immunosuppression has been induced.

[0085] In another example, neutrophil infiltration at the site of inflammation can be measured to assess inflammation. To assess neutrophil infiltration, myeloperoxidase activity can be measured. Oxidase is a blood protein present in the azurophil granules of polymorphonuclear leukocytes and monocytes. Myeloperoxidase converts halide ions to their respective hypohalites. These hypohalous acids are then transported to phagocytes for microbial killing. Therefore, a reduction in myeloperoxidase activity in tissues is desirable. It reflects a reduction in neutrophil infiltration and may serve as a measure of inflammation inhibition.

[0086] In another example, effective treatment of a subject can be determined by measuring cytokine levels in the subject. Cytokine levels in body fluids or cell samples can be measured by This is measured by conventional methods, such as enzyme-linked immunospot or "ELISPOT" assays. An immunospot assay such as Say can be used. It is a highly sensitive quantitative assay for detecting cytokine secretion at the single cell level. The Nospot method and application are well known in the art and are described, for example, in European Patent No. 957359 Variations of the standard immunospot assay are well known in the art, It can be used to detect changes in cytokine production in the methods of the disclosure. (See, e.g., U.S. Patent Nos. 5,939,281 and 6,218,132) (See

[0087] The therapeutically effective amount of MSCs can be administered parenterally, e.g., intravenously, intraperitoneally, intramuscularly, intrasternally, or intracardially. Administration can be by several routes, including intra- or intra-articular injection or infusion.

[0088] Therapeutic Use of MSCs for Use in Inducing Immunosuppression or Treating or Inhibiting Inflammation An effective amount is an amount that achieves a desired effect in the treated subject. The amount of MSCs required to inhibit proliferation or to treat autoimmune or alloimmune diseases The amount of MSCs required to reverse or reverse the symptoms caused by autoimmune diseases, For example, it may be the amount of MSCs that can relieve pain and inflammation. It may be the amount necessary to relieve the associated symptoms, such as pain, edema, and elevated body temperature. This may also be the amount required to reduce or prevent rejection of a transplanted organ. do.

[0089] The MSCs may be administered in a disease-matched treatment regimen, e.g., to ameliorate a disease state. For example, it may be administered once or several times over one to several days, or over the course of the disease. Administered in regular doses over a long period of time to inhibit the progression of the disease and to prevent recurrence of the disease The precise dose to be employed in the formulation will depend on the route of administration and the severity of the disease or disorder. The dose depends on the doctor's judgment and the individual patient's circumstances. The therapeutically effective amount will depend on the subject being treated, the severity and type of affliction, and the mode of administration. In some embodiments, the dose that can be used in treating a human subject is at least At most 3.8 x 10 4 , at least 3.8 × 10 5 , at least 3.8 × 10 6 , less Both 3.8 x 10 7 , at least 3.8 × 10 8 , at least 3.8 × 10 9 or less At most 3.8 x 10 10 regulatory cells / m 2 In certain embodiments, The dose used in treating a subject is about 3.8 x 10 9 ~Approx. 3.8×10 10 control sex cells / m 2 In a further embodiment, the therapeutically effective amount of MSCs may vary from about 5x 10 6 cells / kg body weight~approx. 7.5×10 8 cells / kg body weight, e.g., about 2 x 10 7 Cell~ Approximately 5×10 8 cells / kg body weight or approximately 5 x 10 7 cells ~ approx. 2 x 10 8 Change in cells / kg body weight The exact amount of MSCs may vary based on the age, weight, sex, and physiological condition of the subject. Effective amounts can be readily determined by those skilled in the art using in vitro or animal model tests. These can be extrapolated from dose-response curves derived from experimental systems.

[0090] The expanded MSCs of the present disclosure may be placed in a carrier medium prior to administration. The expanded MSCs of the present disclosure can be cultured in any physiologically acceptable medium, Although they may be administered intravascularly, including intravenously, the appropriate site for regeneration and differentiation is the site of administration of these cells. If the cells are capable of expressing the antibody, they may be introduced into other convenient sites such as the bone marrow. At least about 1 x 10 5cells / kg, at least approximately 5 x 10 5 cells / kg, at least approximately 1×10 6 cells / kg, at least approximately 2 x 10 6 cells / kg, at least approximately 3 x 10 6 Thin At least approximately 4 x 10 cells / kg 6 cells / kg, at least approximately 5 x 10 6 cells / kg, small At least about 6 x 10 6 cells / kg, at least approximately 7 x 10 6 At least about 8 cells / kg x10 6 cells / kg, at least approximately 9 x 10 6 cells / kg, at least approximately 10 x 10 6 Thin Cells / kg or more are administered. See, e.g., Ballen et al. (2001) ) Transplantation 7:635-645. MSCs can be injected The injection can be carried out by any method, including catheterization, etc. Drugs or growth factors may be co-administered, including 5-fluorouracil, ... Rasil, as well as IL-2, IL-3, G-CSF, M-CSF, GM-CSF, and IFN Growth factors include cytokines such as gamma and erythropoietin. MSCs were cultured in the presence of collagen, Matrigel, alone, or with other hydrogels. It can be injected.

[0091] In one embodiment, the expanded MSC population of the present disclosure is derived from injured or diseased Mesenchymal tissues (e.g., heart, pancreas, liver, adipose tissue, bone, cartilage, endothelium, nerve, astrocyte) The expanded MSCs can be used to repair or reconstruct damaged tissues (e.g., the skin, dermis, etc.). Once they migrate or are located at the wound site, they differentiate to form new tissue and organs. In some embodiments, these cells can complement the function of the vascular endothelial cells. These effects are used to improve oxygen delivery and waste removal from tissues. In embodiments, the expanded MSCs of the present disclosure can be used to generate differentiated tissues and organs (e.g., For example, the function of the ischemic heart (as in heart failure) or the ischemic nerve (as in stroke) This can improve performance.

[0092] The expanded MSCs of the present disclosure can be used for gene therapy in patients in need of gene therapy. In some embodiments, particularly where transient gene expression is required. More mature cells may be involved in the transfer of genes, or where cell maturation and division facilitate gene transfer. Lineage-committed cells can be useful. For example, some retroviral vectors can be used to express genes The cells must cycle in order for the proteins to be integrated. To transduce stem and progenitor cells to deliver new therapeutic genes. Methods for this are known in the art.

[0093] The administered MSCs may also be a mixture of the cells described herein and additional cells of interest. Additional cells of interest include differentiated liver cells, differentiated cardiac muscle cells, and differentiated pancreatic cells. These include, but are not limited to, liver cells.

[0094] The expanded MSCs can be used in combination with one or more other therapeutic agents to treat immune-mediated disorders. The combination therapy may include one or more antimicrobial agents (e.g., antibiotics, antivirals, etc.). antifungal agents), antitumor agents (e.g., fluorouracil, methotrexate, paclitaxel, Taxel, fludarabine, etoposide, doxorubicin, or vincristine), immunodepletion Immune-depleting agents (e.g., fludarabine, toposide, doxorubicin, or vincristine), immunosuppressants (e.g., azathioprine, or glucocorticoids, e.g., dexamethasone or prednisone), anti-inflammatory drugs ( For example, glucocorticoids (e.g., hydrocortisone, dexamethasone, or prednisolone) anti-inflammatory drugs (e.g., acetylsalicylic acid, ibuprofen, or or naproxen sodium), cytokines (e.g., interleukin-10 or transforming growth factor-beta), hormones (e.g., estrogen) or These may include, but are not limited to, vaccines. In addition, calcineurin inhibitors ( mTOR inhibitors (e.g., rapamycin); mycophenolate mofetil, antibodies (e.g., CD3, CD4, CD40, CD15 4, antibodies that recognize CD45, IVIG, or B cells; chemotherapeutic agents (e.g., methotrexate) oxalate, treosulfan, busulfan); irradiation; or chemokines, interleukins kinases or their inhibitors (e.g., BAFF, IL-2, anti-IL-2R, IL-4, J immunosuppressants or tolerogenic agents, including but not limited to AK kinase inhibitors Such additional pharmaceutical agents may be administered prior to administration of the regulatory B cells depending on the desired effect. This administration of the cells and agent may be by the same route. or by different routes, and at the same or different sites. .

[0095] IV. Kit In some embodiments, for example, one or more media for generating MSCs and Kits are provided that may contain components. Such formulations may incorporate a cocktail of factors into MSCs. The reagent system may optionally be in an aqueous medium. The container means of the kit may contain the components. At least one vial, test tube, or the like into which the solution may be placed, preferably suitably aliquoted. A container such as a syringe, flask, bottle, syringe or other container means is generally included. If more components are present, the kit will usually contain the additional components separately. However, various components may be present in the container. The combination may be contained in one vial. The components of the kit may be prepared as dry powders. When reagents and / or components are provided as a dry powder, The powder can be reconstituted by adding a suitable solvent, which can be placed in a separate container. It is envisioned that the kits may be provided in a separate package. Kits are typically sold commercially. Also included are means for containing the kit components in a confined state. Examples include injection or blow molded plastic containers that hold the desired vials. The kit may include instructions for use, e.g., in printed or digital form. The instructions may also include instructions in electronic form. [Example]

[0096] V. Working Examples The following examples are included to demonstrate preferred embodiments of the invention. The techniques disclosed in the examples are techniques that the inventors have found to work well in the practice of the present invention. It is well known that the present invention is a legal procedure and therefore may be considered a preferred form for its implementation. However, those skilled in the art will recognize that, in light of this disclosure, Many variations can be made in the specific embodiments described, and these variations are within the spirit and scope of the invention. and that the same or similar results can be achieved without departing from the scope of the present invention. It is.

[0097] Example 1 - Expansion of Mesenchymal Stromal Cells Terumo Quantum Cell Expansion System (used The Bioreactor is an automated hollow fiber cell culture system designed for GMP-compliant cell production. Briefly, umbilical cord tissue is obtained from normal births and cultured with hyaluronidase (HA). Enzyme cocktail containing collagenase NB6 0.5U / ml, hyaluronidase 1U / ml The tissue was digested using 100 μg / ml of PBS and 250 U / ml of DNAse. The cells were plated in a flask and cultured for several days. When the cells reached approximately 85% confluence, Once the cells are confluent, trypsinize them, replate them, and culture them until they are confluent. The cells were harvested at passage 1 (P1) and frozen (Figure 1).

[0098] The P1 cells were then thawed and incubated in a Quantum Bioreactor for 4-6 days. The glucose levels in the bioreactor and the Once the ideal culture density based on TNF-α and lactate levels is identified, the cells are cultured in a controlled manner. This cytokine combination, which includes IFN-γ, IL-1β, and IL-17, was administered for 16 hours. The cells are then activated, washed, harvested, and evaluated in various assays or for clinical use. It was frozen toward (Figure 2).

[0099] 20 million umbilical cord tissue-derived MSCs and bone marrow-derived MSCs were added to the bioreactor. When compared, the number of MSCs generated using umbilical cord tissue was significantly higher than that of bone marrow-derived MSCs in a shorter time. The number of CBt-MSCs was nearly double that of CBt-MSCs (Figure 3). They express the markers Nestin, Stro-1, Oct-4, Nanog, and Cox-2. Importantly, pre-activated CBt-MSCs maintained the baseline (activated) These results suggest that the CBt-MSCs and BM-MSCs were more suppressive than either the activated (non-activated) CBt-MSCs or BM-MSCs (Figure 5). They have higher levels of anti-apoptotic factors (VEGF, TGFβ), anti-inflammatory / anti-proliferative factor (TSG-6), immunomodulatory factor (PD-L1, IDO, PGE2, IL-10, TG Fβ) and chemoattractant homing factors (CXCR4, CXCR3) (Figure 6). Therefore, pre-activated and expanded CBt-MSCs are effective at clinically relevant high doses. These cells were efficiently produced and had a higher therapeutic effect than other MSC preparations (Figure 7).

[0100] Example 2 - Materials and Methods CBt were obtained from consenting healthy mothers of full-term newborns after elective cesarean section. The CBt was transported in Plasmalyte containing penicillin / streptomycin. The CBt was cut into seven equal parts and treated with GentleMACS Octo Dissoci In the ator (Miltenyi), collagenase-NB4 / 6 (Serva) and and hyaluronidase (Sigma-Aldrich), and DNase (Genent C-Tubes (Mil) containing various enzyme combinations with or without enzyme The cell suspension was then filtered and incubated at 37°C for 76 minutes. , washed, and pen-strep with 10% platelet lysate, L-glutamine, and heparin The cells were resuspended in alpha-MEM medium (complete medium) containing 1000 kJ / ml and seeded into a T175 flask. MSCs were cultured in PBS until they reached 80% confluence. Expand to 80% confluence in a T175 flask using complete medium without proteins This was designated as P1.

[0101] After P1 harvest, MSCs were analyzed by flow cytometry for the expression of typical MSC surface markers. The cells were then analyzed by a Quantum Bioreactor ( The CBt-MSCs were expanded in PBS (Terumo) for 5-6 days. The immunosuppressive ability of CBt-MSCs was evaluated using C D4 + T cell proliferation assay (CFSE) and CD4 + T cell cytokine secretion assay Half of the CBt-MSCs were pretreated with interferon gamma. The cells were activated and then seeded into a 96-well plate, with the other half seeded untreated. , that MSCs were isolated 10 5 CD4 + T cells at 1:1, 1:2, 1:10 and All wells except the negative control were incubated with 1:20 PBS. CD3 / 28 beads (ThermoFisher Scientific) were added. The isolated T cells were stained with CFSE for 10 min and then resuspended in 10% fetal bovine serum (FBS) and After incubation, they were co-cultured with MSCs.

[0102] After 72 hours, the wells were treated with BFA (10x), PMA (100x) and ionomycin ( Half of the wells were harvested, washed, and treated with anti-CD4 (Biolegend). and Live-Dead dye (ThermoFisher Scientific). Then, Cytofix / Cytoperm Fixation and P Ermeabilization Solution(BD Biosciences) Following this, 1x buffer was added and the cells were treated with IL-2 (BD), TNF-alpha (BD) and The cells were stained for interferon gamma (BD Biosciences). Next, the remaining wells were collected and stained with anti-CD4-APC (Biolegend) and Live- All samples were stained with Dead (ThermoFisher Scientific). The samples were subjected to flow spectroscopy using a Fortessa X20 (BD Biosciences). Flow cytometry was performed and then analyzed with FlowJo software.

[0103] After enzymatic digestion, the sample without DNase showed poor growth from P0 to P1 (10 The cells were discarded because they were less than 80% confluent by the day. The standard enzyme combination was CBt and DNase. - After seeding the bioreactor with MSCs (ranging from 45 to 62 × 10E6 cells), After 5-6 days of growth in the bioreactor, the median number of cells was 1495 x 10E6. The values ​​of CBt-MSC were obtained (range: 1245-1935×10E6). The median doubling time (the time required for MSCs to proliferate and double in number) of C was 28.2 The time (range 24.5-29.7) was (n=3). The immunosuppression assay was performed using CBtMS. C increased CD4 in a dose-dependent manner + Furthermore, we demonstrated that CB t-MSCs are CD4 + With each successive generation of T cells, stimulated CD4 + on T cells This method reduced the expression of cytokines (IFNγ, TNFα, IL-2). The method describes a novel, standardized, GMP-compliant protocol for the isolation of MSCs from whole CBt. Terumo Bio is a leading provider of CBt-MSCs with immunosuppressive properties. This can be done quickly and efficiently in a reactor.

[0104] Example 3 - Characterization of mesenchymal stem cells The MSCs obtained in Example 1 were characterized in vivo to determine their functions. Fresh CBt-derived MSCs were used in a xenogeneic graft-versus-host disease (GVHD) mouse model. It was found that the treatment extended survival time in the control group (Fig. 8).

[0105] NSG (NOD.Cg-Prkdcscid IL2rgtm1Wjl / SzJ) 7 weeks Male mice were cultured at the Jackson Laboratory (Bar Harbor, ME, USA). The mice (11 weeks old) were purchased from SA and allowed to acclimate for one week before the experiment. Irradiation (300 cGy) was performed, and 24 hours later, on day 0 of the experiment, 2 × 10 6 Individual G-motion The mice were then transplanted with peripheral blood progenitor cells (PBPCs) derived from the BM or CBt. 2 x 10 native MSCs per injection 6 Five doses of +8, +11, +14, +18 and The mice were administered the drug via tail vein injection on days +21 and +22. The survival time, weight loss, fur texture, and physical condition were evaluated. Physical activity, skin integrity, and back flexion were recorded daily. The severity of GVHD was assessed using the clinical scoring system described by. The experiment was performed three times using five mice. The results showed that fresh Significantly prolonged overall survival time in mice receiving BM-derived MSCs or CBT-derived MSCs was shown (Figure 8A).

[0106] In some experiments, a NIR parent molecule was excited at 750 nm and had an emission peak at 782 nm. Xenolight DiR (Perkin Elmer), an oil-soluble carbocyanine dye BM-MSCs or CBt-MSCs were labeled at the University of Illinois (Illinois, Rodgau, Germany). Resuspend the cells in PBS (1 × 10 6 cells / ml), DiR (10 μg DiR / ml) The cells were incubated at 37°C for 30 minutes, and then washed twice with culture medium. Figure 8B shows that the unincorporated dye was removed by ELISA compared to the GVHD control. GVHD in the liver, spleen, and colon of mice treated (with BM- or CBT-MSCs) Histopathological samples demonstrating a slight reduction in symptoms are shown in Figures 8C and 8D. D. Short-term biopsy using DiR immunofluorescence-labeled MSCs injected into mice via the tail vein. CBt-MSCs showed significantly higher intracellular distribution than BM-MSCs over a 72-hour period. A significant improvement in persistence was demonstrated.

[0107] Second, activation of CBt-MSCs resulted in the development of a unique profile with enhanced immunosuppressive properties. CBt-MSCs were cultured in 1% L-glutamine and alpha-MEM medium supplemented with 5% human platelet lysate to 85% confluency. The cells were cultured until the cells reached the end of the incubation period. Then, the medium was changed to an activation medium (1% L-glutamine, IFN-γ, NMDA (10 ng / ml), TNF alpha (10 ng / ml), IL-1B (10 ng / 24-30 days after the initial incubation in alpha-MEM medium supplemented with IL-17 (10 ng / ml) and IL-17 (10 ng / ml). After 36 hours of exchange, cells were harvested and RNA was extracted and purified according to the manufacturer's instructions. (RNeasy Plus Mini Kit, Qiagen). Twelve samples were analyzed per day. RNA extraction, cDNA preamplification, and sequencing After quality control, cDNA libraries were prepared and the transcripts of these cells were analyzed. The genome was sequenced on an Illumina HiSeq2500 system. Analysis of eq data was performed by MD Anderson Bioinformatics. Sequencing reads were aligned to human reference genomes using TOPHAT2 v2.0.1346. The mapped reads were aligned to the hg38 genome (hg38 GE). Counting was performed using HTSEQ47,48 based on the NCODE v25 gene model. Gene expression levels were measured by the EdgeR protocol. The results were analyzed using package 48 with an FDR (false discovery rate) cutoff of <0.01 and a fold change of >2. Ingenuity Pathway Analysis (registered trademark) (IPA Network analysis was performed using Qiagen (registered trademark).

[0108] As summarized in Figure 9A, differentially expressed proteins between resting and activated MSCs A heatmap of genes detected in activated CBt-MSCs compared to quiescent CBt-MSCs shows 816 genes were up-regulated and 383 genes were down-regulated. The effects evaluated for resting and activated UC-MSCs were Gene Ingenuity Pathway Analysis (IPA) is a method for analyzing the activity of cells. Activation disrupts several immune regulatory pathways (e.g., T cell exhaustion, negative regulation of immune responses, IL-6 Induction of gene expression related to signal transduction and induction of T cell apoptosis (Figure 9B).

[0109] Activation and homing of CBt-MSCs in a GVHD xenograft mouse model Enhanced cell proliferation and biodistribution were also observed (Figure 10). IPA analysis performed on RNA extracted from arrested CBt-MSCs compared with those from the control group. homing receptors and markers involved in adhesion and invasion in activated CBtMSCs Several genes involved in extravasation and homing, including important adhesion molecules, The activation of the stimuli was revealed, which is shown in the heat map (Figure 10A). Hormone production in activated CBT MSCs and resting MSCs assessed by cytometry Heat transfer of binding receptors, adhesion molecules, and invasion proteins (metalloproteinases) In the biodistribution experiment, after GvHD induction (PBPC injection on day 0), Resting CBt-MSCs or activated CBt-MSCs pre-labeled with iR were cultured in the caudal vein on day +8. NSG mice were administered intravenous injection (2 × 10 per mouse). 6 MSC).

[0110] As shown in Figures 10C and 10D, after 72 hours of fluorescence analysis, activated CBT -MSCs remained in mice for up to 3 days, longer than control CBt-MSCs As shown in Figure 10E, the results were then analyzed at 3 hours, 48 ​​hours, and After 72 hours, mouse tissues were collected and the mean radiant efficiency was calculated for each tissue. As shown in Figure 10F, Figure 10G for the liver and Figure 10H for the spleen The fluorescence level tended to be higher in the activated CBt-MSC group compared to the control MSC group. The direction was indicated.

[0111] Next, we investigated whether cryopreserved activated UCMSCs had similar effects compared to freshly activated UCMSCs. The results showed that the viability, phenotype, and efficacy of T cell activation regulation were significantly improved (Figure 11). The activated cells were harvested and frozen for two weeks. Afterwards, the cells were thawed and their phenotype was assessed. The results were analyzed using flow cytometry. Figure 11A shows the results of annexin V and iodide protease assay. of CBt-MSCs measured by flow cytometry using the rhopidium assay Representative FACS plots for viability are shown. CBtMSCs (resting and activated) T cell immunosuppression mediated by CFSE was assessed by CFSE assay. Lymphocytes were obtained from PBMNC of healthy volunteers and isolated by Ficoll. PanT cells were isolated using microbeads (Miltenic) and 5(6)-calculated. Fluorescein diacetate N-succinimidyl ester (CFSE; Sigma) They were then stained with lymphocyte medium: 10% FBS, 1% L-glutamine, penicillin (100 units / ml) and streptomycin (100 μ RPMI 1640 medium (Gibco, Grand Island, NY) containing 100 mg / ml For the co-culture assay, 100 μl of MSCs were added to a 96-well plate. The phosphate was added at different concentrations (1×10 6 / ml, 0.5 × 10 6 / ml, 1 × 10 5 / ml) In the above assay, CD3 / CD28 beads (Inv 10 stimulated with ribonucleotides 5 Lymphocytes were seeded onto the MSC monolayer for 4 days. The cells were then harvested, washed, and assayed for viability (Live / Dead Aquia Fluorescence Imaging). T cell proliferation was measured by flow cytometry. The results were evaluated by immunocytochemistry. Naive (unstimulated) lymphocytes (negative control) ), and stimulated T cells without MSCs (positive control) were used as controls. Figure 11B shows a representative histogram of the T cell proliferation CFSE assay. , overall T cells activated with CD3 / CD28 beads at all different ratios Figure 11C shows the persistence of expression of immunosuppressive factors. Representative FACS profiles of activated MSC phenotypes using frozen or frozen / thawed cells. This shows the

[0112] Cryopreserved activated CBt-MSCs prolong overall survival and reduce GVHD toxicity It was also observed that the tumors were more sensitive to radiation (Figure 12). Mice were irradiated with 300 cGy as described above. Within 24 hours after 6 G-mobilized PBPCs were injected with CBt-MSCs Thaw and wash twice with DPBS and place 2 x 10 cells in saline. 6Resuspend at a concentration of 0.1 cells / mL The CBt-MSCs were infused within 3 hours of thawing in all experiments. The control mice were injected with 0.1 mL of saline solution. One mouse was used. Three mice from each group were euthanized on day 24 for histological analysis. Mice were anesthetized, and blood was collected and processed. Human lymphocyte populations were analyzed by flow cytometry. Plasma samples were analyzed and analyzed using a microarray assay. Cytokines were measured. Assays were performed in triplicate.

[0113] Figure 12A-C summarizes the in vivo experiments using groups of mice (n=8 per group). Figure 12A shows the results of untreated (GVHD control) and non-activated CBt-MSC The survival curves of recipients and recipient-activated CBt-MSCs are shown. Data show that activated CBT-MSc compared with non-activated MSC or control Figure 12B shows that activated CBt- The weight change rate is shown, indicating that the MSC recipients experienced less weight loss. 12C shows the mean GVHD score, which indicates that the GVHD scores of the activated CBT-MSC group were significantly higher than those of the control group. Figure 12D shows that the difference in the IL-1 levels between the three groups of mice at the end of the study was significantly lower. Figure 12E shows portal vein liver inflammation compared to untreated mice (control), resting C Mice treated with Bt-MSCs and mice treated with activated (activated) MSCs These blood tests include WBC count, MCV, and MC. HC, hematocrit, hemoglobin, platelet count, RBC count, MCH, RDW, albumin Alkaline phosphatase, potassium, LDH, AST, glucose, ALT, phosphorus, The results show that activated MSCs are more effective than control or non-activated MSCs. Platelet count, glucose, WBC count and liver function (AL) in the group treated with activated MSCs The results show improvement in T, AST.

[0114] Figure 12F shows the results of cytokine levels in the blood of mice, and activated CBt Both CBt-MSCs and non-activated CBt-MSCs reduced inflammatory sites compared with control mice. Figure 12G shows that the presence of IL-1 in the blood of mice on day 24 was significantly reduced. The left panel shows representative FACS images of each group. The right panel shows the statistical comparison with the control group (untreated). 1 shows a bar plot with ** p-value < 0.01, **** A p-value <0.0001 indicates Human CD45 in the blood of both MSC recipient groups + It shows that there are fewer cells This indicates that there were fewer activated MSCs than in non-activated MSC recipients.

[0115] All of the methods disclosed and claimed herein may be practiced without undue experimentation in light of the present disclosure. The compositions and methods of the present invention can be implemented and performed without the need for the following: Although the present invention has been described in terms of its application, no particular limitation or modifications may be made thereto without departing from the concept, spirit and scope of the present invention. that variations may be applied to the methods and method steps or order of steps described therein; More specifically, any combination of chemicals may be used as long as the same or similar results are achieved. Certain biologically and physiologically relevant agents may be substituted for the agents described herein. It will be apparent that such similar substitutes and All modifications falling within the spirit, scope and concept of the invention as defined by the appended claims. is considered to be within

[0116] literature The following references provide exemplary procedures or supplementary information to those described herein: To the extent that other details are provided, they are specifically incorporated herein by reference. Cohen et al., J Immunol. 175:5799-5808, 2005. Current Protocols in Immunology, Ed Coligan et al, Wiley, 1994. Czerkinsky et al., J. Immunol. Methods, 110:29-36, 1988. EP 957359 Fast et al., Transfusion 44:282-5, 2004. Fedorov et al., Sci. Transl. Medicine, 5(215), 2013. He Y, et al. Journal of immunology research, 7, 2014. Heemskerk et al. Hum Gene Ther. 19:496-510, 2008. International Patent Publication No. WO2000 / 06588 International Patent Publication No. WO2000 / 06588 International Publication No. PCT / US95 / 01570 International Publication No. WO2000 / 06588 International Publication No. WO2005 / 035570 Janeway et al, Immunobiology: The Immune System in Health and Disease, 3rd Ed., Current Biology Publications, p. 433, 1997. Johnson et al. Blood 114:535-46, 2009. Lefranc et al., Dev. Comp. Immunol. 27:55, 2003. Li, Nat Biotechnol. 23:349-354, 2005. Olsson et al. J. Clin. Invest. 86:981-985, 1990. Parkhurst et al., Clin Cancer Res. 15: 169-180, 2009. PCT Patent Publication No. WO2001 / 083517 Taitano et al., The Journal of Immunology, 196, 2016. U.S. Patent 7,109,304 U.S. Patent No. 5,939,281 U.S. Patent No. 5,939,281 U.S. Patent No. 6,218,132 U.S. Patent No. 6,218,132 U.S. Patent No. 6,264,951 U.S. Patent No. 6,426,331 U.S. Patent No. 7,488,490 U.S. Patent No. 7,488,490 U.S. Patent Publication No. 2007 / 0078113 Varela-Rohena et al., Nat Med. Rev. 14: 1390–1395. WO2014 / 055668 Wong et al., Cytotherapy, 4:65-76, 2002.

Claims

1. 1. A method for expanding mesenchymal stromal cells (MSCs) from umbilical cord tissue, comprising: (a) treating the umbilical cord tissue with an enzyme cocktail to obtain a population of MSCs from the umbilical cord tissue; and (b) Approximately 1.0×10 6 ~1.0 x 10 8 expanding said population of MSCs in a functionally closed system containing a platelet lysate for 6-8 days to at least 85% confluence to obtain an expanded population of MSCs; A method comprising:

2. The method of claim 1 , wherein the population of MSCs derived from umbilical cord tissue is a population that has been previously cryopreserved.

3. The method of claim 1 , wherein the enzyme cocktail comprises hyaluronidase and collagenase.

4. The method of claim 3, wherein the collagenase is collagenase NB4 / 6.

5. The method of any one of claims 1 to 3, wherein the enzyme cocktail further comprises DNAse.

6. 4. The method of claim 3, wherein the hyaluronidase is at a concentration of 0.5 to 1.5 U / mL.

7. 7. The method of claim 6, wherein the hyaluronidase is at a concentration of 1 U / mL.

8. The method of claim 3 or 4, wherein the collagenase is at a concentration of 0.1 to 1 U / mL.

9. 9. The method of claim 8, wherein the collagenase is at a concentration of 0.5 U / mL.

10. The method of claim 5, wherein the DNAse is at a concentration of 200 to 300 U / mL.

11. 11. The method of claim 10, wherein the DNAse is at a concentration of 250 U / mL.

12. The method of claim 1 , wherein the functionally closed system is a bioreactor.

13. 13. The method of claim 12, wherein the bioreactor is a hollow fiber bioreactor.

14. The method of any one of claims 1 to 13, wherein the expansion step is carried out for less than 7 days.

15. The method according to any one of claims 1 to 14, wherein the expansion step is carried out for 5 to 6 days.

16. The method of any of claims 1 to 15, wherein the MSCs are expanded at least 50-fold.

17. The method of any of claims 1 to 16, wherein the MSCs are expanded at least 70-fold.

18. The method of any of claims 1 to 17, wherein the MSCs have a doubling time of less than 28 hours.

19. The method of any of claims 1 to 18, wherein the method is GMP compliant.

20. The method of any of claims 1 to 19, further comprising the step of cryopreserving the pre-activated MSCs.

21. A pharmaceutical composition comprising MSCs produced by a method comprising the steps of: (a) treating the umbilical cord tissue with an enzyme cocktail to obtain a population of MSCs from the umbilical cord tissue; (b) Approximately 1.0×10 6 ~1.0 x 10 8 and expanding said population of MSCs in a functionally closed system containing a platelet lysate for 6-8 days to at least 85% confluence to obtain an expanded population of MSCs.

22. 22. The composition of claim 21 for use in the treatment of an inflammatory disease.

23. 23. The composition of claim 22, wherein the inflammatory disease is graft-versus-host disease (GVHD), an autoimmune disease, acute ischemic stroke, myocardial injury, acute respiratory distress syndrome (ARDS) or inflammatory bowel disease.

24. The composition of any one of claims 21 to 23, wherein the MSCs are allogeneic.

25. The composition of any one of claims 21 to 24, wherein the MSCs are administered systemically or locally.

26. 26. The composition of any of claims 21-25, wherein the MSCs are administered via a rectal, nasal, buccal, vaginal, subcutaneous, intradermal, intravenous, intraperitoneal, intramuscular, intra-articular, intrasynovial, intrasternal, intrathecal, intralesional or intracranial route or via an implanted reservoir.

27. The composition of any of claims 21 to 26, wherein the MSCs are administered together with at least one additional therapeutic agent.

28. 28. The composition of claim 27, wherein the at least one additional therapeutic agent is a therapeutically effective amount of an immunomodulatory or immunosuppressant agent.

29. 29. The composition of claim 28, wherein the immunosuppressant is a calcineurin inhibitor, an mTOR inhibitor, an antibody, a chemotherapeutic agent, radiation, a chemokine, an interleukin, or an inhibitor of a chemokine or an interleukin.

30. The MSCs are about 5×10 6 Cells: Approximately 7.5 x 10 per kg of body weight 8 The composition according to any one of claims 21 to 29, which is administered in a cell.

Citation Information

Patent Citations

  • Methods for isolation and expansion of umbilical cord mesenchymal stem cells

    WO2017132358A1

  • Mesenchymal stem cells with enhanced efficacy

    WO2017160986A1